Exclusivity For Vyvanse Upheld - U.S. Pharmacist

Maybe your like

Pharmacy Practice Affordable Medicines Biosimilars Compliance Compounding Drug Approvals Geriatrics Hospital/Health System In-Pharmacy Vaccines Law Medication Management News & Trends OTC Pharmacist Resources Pharmacy Technician Pharmacy Week Specialty Pharmacy Technology
Disease State Allergy Asthma Autoimmune Breast Cancer Cardiovascular Cold & Flu Diabetes Technology COPD COVID-19 Dermatology Diabetes Epilepsy Gastroenterology Hematology Hepatitis HIV/AIDS Huntington's Disease Infectious Disease Infusion Lung Cancer Meningitis Menopause Mental Health mRNA Technology Nash Neurology Oncology Ophthalmology Orthopedics Osteoporosis Pain Management Pediatrics Pneumococcal Vaccine Pneumonia Prescription Weight Management Respiratory Rheumatoid Arthritis RSV Schizophrenia Shingles Transplant Travel Health Urology/Nephrology Women’s Health
Health Awareness Month
Videos
Patient Teaching Aid
Publications Featured Issue Featured Supplements
Conference Coverage
Continuing Education

US Pharm. 2010;35(12):104.

Shire plc announced that the U.S. Court of Appeals for the District of Columbia Circuit affirmed the ruling of the U.S. District Court for the District of Columbia and the FDA to grant 5-year New Chemical Entity exclusivity to lisdexamfetamine dimesylate, currently marketed by Shire U.S. Inc. under the name Vyvanse. The 5-year exclusivity period for Vyvanse expires on February 23, 2012. Vyvanse is further protected by U.S. patents, the first of which expires on June 29, 2023. As a result of the ruling, generic manufacturers cannot submit an abbreviated new drug application (ANDA) to the FDA until February 23, 2011. X